Olena Tsyryuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olena Tsyryuk has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ludovico Abenavoli
Department of Health Sciences, University “Magna Graecia”, 88100 Catanzaro, Italy
1 shared publication - Luigi Boccuto
Healthcare Genetics and Genomics Program, School of Nursing, Clemson University, Clemson, SC 29634, USA
1 shared publication - Nazarii Kobyliak
Bogomolets National Medical University
1 shared publication - Tetyana Falalyeyeva
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 11 October 2018
- Published by MDPI AG in Pharmaceuticals
- Vol. 11 (4) , 104
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.
- 11 October 2018
- Published by MDPI AG in Pharmaceuticals
- Vol. 11 (4) , 104
Open AccessObeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.